Business
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL, November 06, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November:
About this update from Engene Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/486f55e6eaf3a9669c7f567dc77c4fd9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qu65OhgAjRN.vQEVPc6rvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/486f55e6eaf3a9669c7f567dc77c4fd9","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.tpFpOhpvGLT4Hqo9YpgnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/486f55e6eaf3a9669c7f567dc77c4fd9","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BOSTON & MONTREAL, November 06, 2025--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences in November:","length":272,"tagName":"p"},{"type":"text","content":"Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Tuesday, November 11, 2025Time: 12:30 p.m. ET","length":107,"tagName":"p"},{"type":"text","content":"Stifel 2025 Healthcare ConferenceDate: Wednesday, November 12, 2025Time: 2:00 p.m. ET","length":87,"tagName":"p"},{"type":"text","content":"Jefferies Global Healthcare Conference in LondonDate: Tuesday, November 18, 2025Time: 8:30 a.m. GMT / 3:30 a.m. ET","length":116,"tagName":"p"},{"type":"text","content":"A live webcast of these events can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days.","length":166,"tagName":"p"},{"type":"text","content":"About enGene","length":12,"tagName":"p"},{"type":"text","content":"enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a p...